Source: Pathology in Practice
Biomarkers have evolved from simple disease indicators to essential tools in clinical trials, enabling researchers to monitor disease progression and evaluate treatment effectiveness.
Michael Miller, Chief Operating Officer, shared with Pathology In Practice, that recently validated blood-based biomarkers, such as p-tau217, enable earlier and more confident Alzheimer’s diagnosis without costly PET or CSF tests—reducing delays, lowering healthcare burden, expanding global access and allowing patients to start potentially more effective treatments sooner.
Read the article to learn how collaboration between diagnostic and pharmaceutical leaders can accelerate biomarker discovery and development, providing researchers with resources and a streamlined path from early research to clinical applications, ensuring treatments reach the patients that need them most.
Multi-omic diagnostics are reshaping how researchers and clinicians approach complex diseases, offering deeper biological insights through the integration of multiple data types. In this interview with The Pathologist, industry experts…
Spatial Analysis
A Q&A with Kishore Malyavantham, PhD, VP of R&D at Quanterix and Co-Investigator, PD-BUILD Quanterix has been named a Co-Investigator institution in PD-BUILD (Biomarker Utilization, Innovation, and Laboratory-to-Deployment), a new project…
Part of a global effort to advance Parkinson’s disease biomarkers through standardized, scalable assay development Quanterix has been selected as a Co-Investigator institution in the PD-BUILD program, part of the…
Neurology
Quanterix makes the case with ctDNA in oncology, p-tau217 in Alzheimer’s and a lab model built for longitudinal, regulatory-grade data. Biomarkers have moved from “nice-to-have” to the backbone of drug…
Neurology
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, outlined strategies for integrating blood-based biomarkers into routine clinical care pathways, ensuring minimal disruption for patients and clinicians. Watch the full…
Neurology
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed challenges in positioning Simoa in the precision health market, stressing its accuracy and reliability in diverse populations. Watch the full…
Neurology
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed translating complex scientific findings into actionable insights for healthcare providers and stakeholders, emphasizing the importance of early disease detection. Watch…
